RESUMO
Introduction: Safe administration of critical care hyperbaric medicine requires specialized equipment and advanced training. Equipment must be tested in order to evaluate function in the hyperbaric environment. High-frequency percussive ventilation (HFPV) has been used in intensive care settings effectively, but it has never been tested in a hyperbaric chamber. Methods: Following a modified U.S. Navy testing protocol used to evaluate hyperbaric ventilators, we evaluated an HFPV transport ventilator in a multiplace hyperbaric chamber at 1.0, 1.9, and 2.8 atmospheres absolute (ATA). We used a test lung with analytical software for data collection. The ventilator uses simultaneous cyclic pressure-controlled ventilation at a pulsatile flow rate (PFR)/oscillatory continuous positive airway pressure (oCPAP) ratio of 30/10 with a high-frequency oscillation percussive rate of 500 beats per minute. Inspiratory and expiratory times were maintained at two seconds throughout each breathing cycle. Results: During manned studies, the PFR/oCPAP ratios were 26/6, 22/7, and 22.5/8 at an airway resistance of 20cm H2O/L/second and 18/9, 15.2/8.5, and 13.6/7 at an airway resistance of 50 cm/H2O/L/second at 1, 1.9, and 2.8 ATA. The resulting release volumes were 800, 547, and 513 mL at airway resistance of 20 cm H2O/L/sec and 400, 253, and 180 mL at airway resistance of 50 cm/H2O/L/sec at 1, 1.9, and 2.8 ATA. Unmanned testing showed similar changes. The mean airway pressure (MAP) remained stable throughout all test conditions; theoretically, supporting adequate lung recruitment and gas exchange. A case where HFPV was used to treat a patient for CO poisoning was presented to illustrate that HFPV worked well under HBO2 conditions and no complications occurred during HBO2 treatment. Conclusion: The HFPV transport ventilator performed adequately under hyperbaric conditions and should be considered a viable option for hyperbaric critical care. This ventilator has atypical terminology and produces unique pulmonary physiology, thus requiring specialized training prior to use.
Assuntos
Ventilação de Alta Frequência/instrumentação , Oxigenoterapia Hiperbárica/instrumentação , Lesão por Inalação de Fumaça/terapia , Ventiladores Mecânicos , Acidose/etiologia , Idoso , Resistência das Vias Respiratórias , Pressão Atmosférica , Intoxicação por Monóxido de Carbono/complicações , Feminino , Ventilação de Alta Frequência/métodos , Humanos , Oxigenoterapia Hiperbárica/métodos , Pulmão/fisiologia , Respiração com Pressão Positiva/instrumentação , Respiração com Pressão Positiva/métodos , Troca Gasosa Pulmonar/fisiologia , Fluxo Pulsátil , Valores de Referência , RespiraçãoRESUMO
The SARS-Cov-2 (COVID-19) pandemic remains a major worldwide public health issue. Initially, improved supportive and anti-inflammatory intervention, often employing known drugs or technologies, provided measurable improvement in management. We have recently seen advances in specific therapeutic interventions and in vaccines. Nevertheless, it will be months before most of the world's population can be vaccinated to achieve herd immunity. In the interim, hyperbaric oxygen (HBO2) treatment offers several potentially beneficial therapeutic effects. Three small published series, one with a propensity-score-matched control group, have demonstrated safety and initial efficacy. Additional anecdotal reports are consistent with these publications. HBO2 delivers oxygen in extreme conditions of hypoxemia and tissue hypoxia, even in the presence of lung pathology. It provides anti-inflammatory and anti-proinflammatory effects likely to ameliorate the overexuberant immune response common to COVID-19. Unlike steroids, it exerts these effects without immune suppression. One study suggests HBO2 may reduce the hypercoagulability seen in COVID patients. Also, hyperbaric oxygen offers a likely successful intervention to address the oxygen debt expected to arise from a prolonged period of hypoxemia and tissue hypoxia. To date, 11 studies designed to investigate the impact of HBO2 on patients infected with SARS-Cov-2 have been posted on clinicaltrials.gov. This paper describes the promising physiologic and biochemical effects of hyperbaric oxygen in COVID-19 and potentially in other disorders with similar pathologic mechanisms.
Assuntos
COVID-19/terapia , Oxigenoterapia Hiperbárica/métodos , COVID-19/sangue , COVID-19/complicações , COVID-19/imunologia , Hipóxia Celular , Síndrome da Liberação de Citocina/imunologia , Citocinas/sangue , Humanos , Hipóxia/terapia , Inflamação/terapia , Células-Tronco Mesenquimais , Oxigênio/intoxicação , Consumo de Oxigênio , Trombofilia/etiologia , Trombofilia/terapiaRESUMO
The use of hyperbaric oxygen (HBO2) for the treatment of selected problem wounds has focused almost entirely on the diabetic foot ulcer (DFU) in recent years. The prevalence of DFUs in today's patient population and the reimbursement available for the treatment of DFUs have given it priority status in discussions about problem wounds, but there are sound fundamental reasons why additional oxygen may have benefits in the treatment of non-DFU wounds.
Assuntos
Oxigenoterapia Hiperbárica/métodos , Oxigênio/fisiologia , Úlcera Cutânea/terapia , Cicatrização/fisiologia , Ferimentos e Lesões/terapia , Anemia Falciforme/complicações , Calciofilaxia/terapia , Pé Diabético/fisiopatologia , Pé Diabético/terapia , Doença Enxerto-Hospedeiro/terapia , Humanos , Salvamento de Membro , Metanálise como Assunto , Pressão Parcial , Seleção de Pacientes , Doença Arterial Periférica/fisiopatologia , Doença Arterial Periférica/terapia , Guias de Prática Clínica como Assunto , Pioderma Gangrenoso/fisiopatologia , Pioderma Gangrenoso/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Doença de Raynaud/fisiopatologia , Doença de Raynaud/terapia , Escleroderma Sistêmico/fisiopatologia , Escleroderma Sistêmico/terapia , Úlcera Cutânea/etiologia , Úlcera Cutânea/fisiopatologia , Revisões Sistemáticas como Assunto , Resultado do Tratamento , Revisão da Utilização de Recursos de Saúde , Ferimentos e Lesões/complicaçõesRESUMO
Objective: The goal of this research was to identify a population of diabetic foot ulcer patients who demonstrate a significant response to hyperbaric oxygen therapy (HBOT) using a large sample size to provide guidance for clinicians when treating these complicated patients. Approach: The effect of HBOT on diabetic foot ulcers, Wagner grades 3 and 4, was evaluated using a retrospective observational real-world data set. The study reported on the overall healing rate, (74.2%) at the population level, for >2 million wounds. Results: When a subgroup of patients of only foot ulcers with a Wagner grade 3 or 4 were considered, the healing rate was only 56.04%. The use of HBOT, without filtering for the number of treatments received, improved the healing rate to 60.01% overall. Healing rates for this same subgroup, however, were improved to 75.24% for patients who completed the prescribed number of hyperbaric treatments. Innovation: This observational study discusses the importance of reporting at the population level, specific wound etiology level, a risk-stratified level, and to then overlay the effect of treatment adherence on those outcomes to provide clinicians with a comprehensive understanding of when to prescribe an advanced modality such as hyperbaric oxygen. Conclusion: The authors provide healing outcomes data from several prior HBOT studies as well as other advanced modalities that have been used in diabetic foot ulcer care for comparison and context.
Assuntos
Instituições de Assistência Ambulatorial/provisão & distribuição , Acessibilidade aos Serviços de Saúde/tendências , Hospitais Especializados/provisão & distribuição , Oxigenoterapia Hiperbárica/tendências , Acreditação , Instituições de Assistência Ambulatorial/tendências , Currículo , Tratamento de Emergência/economia , Hospitais Especializados/tendências , Humanos , Oxigenoterapia Hiperbárica/economia , Reembolso de Seguro de Saúde/legislação & jurisprudência , Reembolso de Seguro de Saúde/tendências , Uso Excessivo dos Serviços de Saúde/economia , Uso Excessivo dos Serviços de Saúde/legislação & jurisprudência , Estados UnidosRESUMO
BACKGROUND: The role of hyperbaric oxygen (HBO2) for the treatment of diabetic foot ulcers (DFUs) has been examined in the medical literature for decades. There are more systematic reviews of the HBO2/DFU literature than there have been randomized controlled trials (RCTs), but none of these reviews has resulted in a clinical practice guideline (CPG) that clinicians, patients and policy-makers can use to guide decision-making in everyday practice. METHODS: The Undersea and Hyperbaric Medical Society (UHMS), following the methodology of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, undertook this systematic review of the HBO2 literature in order to rate the quality of evidence and generate practice recommendations for the treatment of DFUs. We selected four clinical questions for review regarding the role of HBO2 in the treatment of DFUs and analyzed the literature using patient populations based on Wagner wound classification and age of the wound (i.e., acute post-operative wound vs. non-healing wound of 30 or more days). Major amputation and incomplete healing were selected as critical outcomes of interest. RESULTS: This analysis showed that HBO2 is beneficial in preventing amputation and promoting complete healing in patients with Wagner Grade 3 or greater DFUs who have just undergone surgical debridement of the foot as well as in patients with Wagner Grade 3 or greater DFUs that have shown no significant improvement after 30 or more days of treatment. In patients with Wagner Grade 2 or lower DFUs, there was inadequate evidence to justify the use of HBO2 as an adjunctive treatment. CONCLUSIONS: Clinicians, patients, and policy-makers should engage in shared decision-making and consider HBO2 as an adjunctive treatment of DFUs that fit the criteria outlined in this guideline. The current body of evidence provides a moderate level of evidence supporting the use of HBO2 for DFUs. Future research should be directed at improving methods for patient selection, testing various treatment protocols and improving our confidence in the existing estimates.